利特西替尼

Description

Ritlecitinib · CAS 1792180-81-4 · C15H19N5O. UNII 2OYE00PC25.

Identification

CAS Registry Number	1792180-81-4
PubChem CID	118115473
Molecular formula	C15H19N5O
IUPAC name	1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
UNII (FDA)	2OYE00PC25

Computed Descriptors

Molecular Weight	285.34
XLogP3	2.1
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	3
Exact Mass	285.15896025
Monoisotopic Mass	285.15896025
Topological Polar Surface Area	73.9
Heavy Atom Count	21
Formal Charge	0

GHS Hazard Classification

Reported hazard statements	H361 (100%)

Documented Uses

• Ritlecitinib is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. It is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
• Ritlecitinib is an orally available small molecule inhibitor of Janus kinase 3 (JAK3) that is used to treat severe alopecia areata. Ritlecitinib is associated with a low rate of transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to cases of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Milk, Human; Breast Feeding; Enzyme Inhibitors; Janus Kinase Inhibitors; JAK Inhibitors
• Breast Feeding; Lactation; Milk, Human; Enzyme Inhibitors; Janus Kinase Inhibitors; JAK Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors
• Take with or without food. The coadministration of ritlecitinib and a high-fat meal reduced the Cmax and AUC; however, food does not have a clinically significant impact on the systemic exposures of ritlecitinib.
• Agents that inhibit JANUS KINASES.

Synonyms

ritlecitinib; 1792180-81-4; PF-06651600; 2OYE00PC25; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one; 2-Propen-1-one, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-; PF06651600; PF 06651600; 2-PROPEN-1-ONE, 1-((2S,5R)-2-METHYL-5-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-1-PIPERIDINYL)-; 1-((2S,5R)-2-methyl-5-((7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one; 1-((2S,5R)-2-methyl-5-(7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)piperidin-1-yl)prop-2-en-1-one; 1-[(2S,5R)-2-methyl-5-{7H-pyrrolo[2,3-d]pyrimidin-4-ylamino}piperidin-1-yl]prop-2-en-1-one; 1-{(2S,5R)-2-Methyl-5-[(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}prop-2-en-1-one; RefChem:179511; JAK3 Inhibitor PF-06651600; 815-269-7

Frequently Asked Questions

What are the CAS number and molecular formula of Ritlecitinib?

CAS 1792180-81-4; molecular formula C15H19N5O; molecular weight — g/mol.

What other names is Ritlecitinib known by?

ritlecitinib, 1792180-81-4, PF-06651600, 2OYE00PC25, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one, 2-Propen-1-one, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-.

Is Ritlecitinib classified as hazardous?

Hazard statements reported: H361.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.